New Study Finds Significant Improvements in DED Following Use of Eye Eco Tranquileyes XL and Tranquilvibes Hydrating Masks

Eye Eco announced results of a study validating the clinical benefits of its moist heat masks, Tranquilvibes and Tranquileyes XL, for improving the signs and symptoms of dry eye disease caused by meibomian gland dysfunction (MGD). Patients who used the masks to treat tired, dry, gritty, inflamed eyes felt better, improved corneal health and showed nearly 70% improvement in tear film stability, according to a company news release.

Dry eye disease has been diagnosed in more than 16 million American adults,¹ but prevailing opinion puts the undiagnosed number higher, especially as screen time continues to escalate. About 86% of dry eye is caused by MGD in the eyelids,² for which first-line treatment is warm compresses. Tranquileyes XL and Tranquilvibes masks were designed to make warm compresses for MGD easy, effective and uniformly predictable, with optimum heat (102-110° F) and humidity (89-94%).

“Dry eye is a chronic, progressive condition caused primarily by MGD that requires home care for effective management. Eye care practitioners are always looking for ways to make home care simpler and more effective,” Leslie O’Dell, OD, the study’s lead investigator, said in the news release. “In this study, the combination of heat and humidity in Tranquileyes XL and in Tranquilvibes, which adds vibration to massage the eyelids, significantly improved both dry eye symptoms and objective markers of ocular surface health. It’s clearly a very effective warm compress mask for dry eye patients.”

In the randomized multicenter observer-masked study, 35 patients with similar MGD-associated dry eye disease underwent in-office treatment with Tranquilvibes followed by manual gland expression, and then used Tranquilvibes or Tranquileyes XL at home for 20-minute moist heat treatments daily. After 30 days, both groups showed about a 32% better symptom scores, as well as improvements in tear breakup time (~70% increase), conjunctival and corneal staining (~40% and ~30%), conjunctival injection (45%), and anterior blepharitis (~32%). No adverse events were reported.

“It’s particularly gratifying to see Dr. O’Dell’s data show just what a compelling difference Tranquilvibes and Tranquileyes XL make for patients with moderate and severe MGD,” said Eye Eco CEO Suzanne Paulson. “Eye Eco’s dedicated goal is to offer natural, drug-free solutions that alleviate the frustrating symptoms of MGD and dry eye disease, and the data show our treatment technologies are achieving that goal.”

References

1. Farrand KF, Fridman M, Stillman IO, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol 2017;182:90-8.
2. Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May;31(5):472-8.